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Abstract
Background: Inherited neurometabolic disorders (iNMDs) represent a group of almost seven hundred rare diseases
whose common manifestations are clinical neurologic or cognitive symptoms that can appear at any time, in the first
months/years of age or even later in adulthood. Early diagnosis and timely treatments are often pivotal for the favorable
course of the disease. Thus, the elaboration of new evidence-based recommendations for iNMD diagnosis and
management is increasingly requested by health care professionals and patients, even though the methodological
quality of existing guidelines is largely unclear. InNerMeD-I-Network is the first European network on iNMDs that was
created with the aim of sharing and increasing validated information about diagnosis and management of
neurometabolic disorders. One of the goals of the project was to determine the number and the methodological quality
of existing guidelines and recommendations for iNMDs.
Methods: We performed a systematic search on PubMed, the National Guideline Clearinghouse (NGC), the Guidelines
International Network (G-I-N), the Scottish Intercollegiate Guideline Network (SIGN) and the National Institute for Health
and Care Excellence (NICE) to identify all the published guidelines and recommendations for iNMDs from January 2000
to June 2015. The methodological quality of the selected documents was determined using the AGREE II instrument, an
appraisal tool composed of 6 domains covering 23 key items.
Results: A total of 55 records met the inclusion criteria, 11 % were about groups of disorders, whereas the
majority encompassed only one disorder. Lysosomal disorders, and in particular Fabry, Gaucher disease and
mucopolysaccharidoses where the most studied. The overall methodological quality of the recommendation
was acceptable and increased over time, with 25 % of the identified guidelines strongly recommended by
the appraisers, 64 % recommended, and 11 % not recommended. However, heterogeneity in the obtained
scores for each domain was observed among documents covering different groups of disorders and some
domains like 'stakeholder involvement' and 'applicability' were generally scarcely addressed.
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Conclusions: Greater efforts should be devoted to improve the methodological quality of guidelines and
recommendations for iNMDs and AGREE II instrument seems advisable for new guideline development.
The elaboration of new guidelines encompassing still uncovered disorders is badly needed.
Keywords: Inherited neurometabolic disorders, Inborn errors of metabolism, Guidelines, Recommendations, AGREE II
Background
Inherited neurometabolic disorders (iNMDs) comprise
almost seven hundred different rare diseases resulting
from genetic defects, ranging from abnormal amino acid
metabolism, impaired mitochondrial function, abnormal
lipid trafficking to lysosomal storage diseases [1, 2]. The
genetic defects affecting metabolic enzymes impact on
the brain from birth and during the whole developmental
period of childhood till adulthood, causing diverse neuro-
logical manifestations [3, 4].
INMDs, because of their rarity, still represent a
challenge for many clinicians who are not able to
properly diagnose, treat or follow-up affected patients.
In addition, although effective treatments improving
the life expectancy and/or quality of life exist for
some iNMDs, they are often too expensive, not avail-
able in all countries or even administered too late.
Clinical practice guidelines (GLs) are commonly defined
as “systematically developed statements to assist practi-
tioner and patient decisions about appropriate health care
for specific clinical circumstances” [5]. There are very few
GLs and recommendations (RCs) that can assist patients,
families, health professionals and support services to
correctly manage iNMDs, and their methodological
quality has never been systematically evaluated. For this
reason, it may be also difficult for practitioners to choose
the appropriate recommendations.
Because of the paucity of current information about
most of these disorders, the European project "Inher-
ited NeuroMetabolic Disease Information Network"
(InNerMeD-I-Network, 2012 12 12, second Health
Programme, http://www.innermed.eu) was launched
with the aim of creating a network of information
related to diagnosis and treatment of iNMDs. INMDs
were classified in ten different categories, starting from
previous existing classifications (http://www.orpha.net):
(1) disorders of amino acids and organic acids; (2) purine,
pyrimidine and neurotrasmitter metabolism diseases (3)
disorders of carbohydrate metabolism; (4) disorders of
lipid metabolism; (5) disorders of vitamin and non protein
cofactor metabolism and transport; (6) disorders of
porphyrin and hem metabolism; (7) disorders of min-
eral absorption and transport; (8) disorders of energy
metabolism; (9) disorders of lysosomal and lysosomal-
related organelles and (10) peroxisomal diseases. Re-
cently, a new category of inborn errors of metabolism
(IEMs) that currently includes more than one hun-
dred diseases has been described: the defects of syn-
thesis and remodeling of complex lipids [6].
In the present study we performed a systematic review of
the literature to identify all published GLs and RCs about
iNMDs. The aim of this study was to evaluate the number
and the methodological quality of the GLs and RCs on
iNMDs published from 2000 to 2015. To this purpose, we
used the Appraisal of Guidelines, Research, and Evaluation
II (AGREEII) instrument, a tool that evaluates the rigour
and transparency in GL development and how well this
process is reported [7–9]. A systematic analysis of the exist-
ing GLs and RCs for iNMDs may be useful for new guide-
line developers willing to follow a structured and rigorous
elaboration methodology.
Methods
Search strategy
For each of the 682 identified iNMDs, grouped in ten
categories, the following electronic databases related to
GLs and RCs were systematically searched on February-
March 2015: PubMed (http://www.ncbi.nlm.nih.gov/
pubmed); the National Guideline Clearinghouse (NGC,
http://www.guideline.gov); the Guidelines International
Network (G-I-N, http://www.g-i-n.net); the Scottish
Intercollegiate Guideline Network (SIGN, http://
www.sign.ac.uk); the National Institute for Health and
Care Excellence (NICE, http://www.nice.org.uk). Add-
itional publications were included after manually
checking the reference lists of the identified relevant
documents. The strategy used to identify the GLs and
RCs is shown in Fig. 1.
For PubMed database, the following searching strategy
was used for each of the 682 diseases:
#1: “Disease" [Mesh]
#2: “Disease"
#3: #1 OR #2
#4: Recomm* OR Management OR update [TI/AB] OR
Therapeutic* [TI/AB] OR treatment* OR guideline*
OR consensus OR standard OR criterion [TI/AB]))
OR ("Disease Management" [Mesh] OR "Therapeu-
tics" [Mesh] OR "Health Planning Guidelines" [Mesh]
OR "Guidelines as Topic" [Mesh] OR "Practice guide-
lines as Topic" [Mesh] OR "Review" [Publication
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Type] OR "Guideline" [Publication Type] OR
"Practice Guideline" [Publication Type].
#5: #3 AND #4.
Search terms: disease, recommendation, management,
update, therapeutic, treatment, guideline, consensus,
standard, criterion, disease management, health planning
guidelines, practice guideline, review.
Inclusion and exclusion criteria
All the GLs and RCs published from 2000 to 2015 in the
mentioned databases were selected by one of the authors
(LC). Only English-written publications were considered.
Duplicates of documents, which were found in more
than one database, were manually removed from the
selection. The initial search yielded unique records based
on title and abstract (Fig. 1).
The final documents were then selected by two
authors (LC and AGC) after reading the full text.
First and updated versions of the same GLs and RCs
were considered as distinct documents. Publications
were excluded when the method used to formulate
the GL or RC did not include a formal consensus
process (such as the one reached through the Delphi
Method or repetitive encounters) among independent
professional groups or individuals. Moreover, GLs and
RCs were not considered when they are applicable to
one unique country. Reviews, algorithms and letters
were also excluded. The selected unique records that
responded to all the criteria for evaluation cover
disorders related to:
Fig. 1 Flowchart of the strategy used to search and select GLs and RCs. A systematic search of the literature was performed in order to identify
GLs and RCs encompassing 682 iNMDs. The documents were firstly selected on the basis of title and abstract (251 items). The analysis of the full
text, as well as the application of the exclusion criteria, returned 55 unique documents that underwent AGREE II appraisal. GL: guideline; RC:
recommendation; NGC: National Guideline Clearinghouse; G-I-N: Guideline International Network; SIGN: Scottish Intercollegiate Guideline Network;
NICE: National Institute for Health and Care Excellence; AGREE: Appraisal of Guidelines, Research, and Evaluation
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Defects of synthesis and remodeling of complex lipids
were not considered in the search, because many of them
are emerging disorders described in the last recent years.
For each study the following data were extracted: year
of publication, name of the covered disease, number of
authors, number of countries involved, country of origin
of the authors, number of affiliations, and topics (screen-
ing, diagnosis, management and follow-up).
Appraisal of guidelines and recommendations
The AGREE II instrument was used to assess the trans-
parency, the methodological quality and the rigour of
the selected GLs and RCs. It consists of 23 key items
that address six quality domains: (1) scope and purpose,
(2) stakeholder involvement, (3) rigor of development,
(4) clarity of presentation, (5) applicability and (6)
editorial independence. Two additional items concern
the overall judgment of the GL (Overall Guideline
Assessment) (Table 1).
The detailed criteria for each item are available in the user
manual for AGREE II tool (http://www.agreetrust.org/).
Briefly, for each document, the twenty-three items
were rated on a 7-point scale (1–strongly disagree to
7–strongly agree) by two trained independent reviewers,
experts in the field of IEMs and belonging to clinical, bio-
chemical or genetic professional categories. One reviewer
(LC) trained all the reviewers and rated all the documents,
in order to provide a minimum variability between ap-
praisals. A score of 1 was given when little or no relevant
information was presented and a score of 7 was given
when the statement met all criteria. Disagreement
between reviewers (defined as ≥3 points difference in the
score assigned by the appraisers to the same item) was
resolved through consensus. To achieve consensus, the
two reviewers shared the rationale for their appraisal and
helped by the instructions provided by AGREE II instru-
ment, they reached an agreement. According to AGREE II
instructions, domain scores were calculated as (obtained
score –minimum possible score)/(maximum possible
score – minimum possible score) where "obtained score"
is determined by summing up all the scores given by the
appraisers for the individual items in a domain. All the
final domain scores were entered into an Excel spread-
sheet. Since the AGREE II manual does not provide guid-
ance regarding how to interpret scores, to determine the
grade of recommendation of the GL/RC we used a
method previously applied by other authors with some
minor modifications [10].
A GL or RC is “strongly recommended (SR)” when
all the six item scores were ≥50 % or five item scores
were ≥50 % and one item score was between 40 and
50 %. A guideline is “recommended (R)” if the overall
quality assessment (OQA) score was ≥50 %. A guideline is
“not recommended (NR)” if the OQA score was < 50 %.
The term GL and RC was assigned to the documents
on the basis of the definition that the developers used to
define the guidance they elaborated. However, all the
articles underwent the same AGREE II appraisal process,
regardless if they were GLs or RCs.
Statistics
Data analysis was performed using the SPSS 22.0 software.
The Kolmogorov-Smirnov test was applied to assess the
data distribution. The ANOVA test was applied to
compare score means of domains and individual questions
between the established guideline groups. To study differ-
ences between GL groups, either parametric tests (if they
follow a Gaussian distribution, Bonferroni Test) or non-
parametric test (Games-Hewell) were applied. Pearson
correlation test was applied to search for correlation be-
tween year of publication and number of GLs or RCs, and
overall quality. Finally, the correlation between the quality
of a GL and the number of authors, countries and affilia-
tions involved was assessed. Statistical significance was
defined as p < 0.05.
Results
A total of 251 unique documents about detection or
management of iNMDs are available so far and 87.3 %
were published from 2000. The NGC defines GLs as
"statements that include recommendations intended to
optimize patient care that are informed by a systematic
review of evidence and an assessment of the benefits and
harms of alternative care options". Following this defin-
ition of GL and applying the inclusion and exclusion
criteria shown in Fig. 1, only 21.9 % of the documents
analyzed (n = 55) corresponded to GLs and RCs eligible
for AGREE II appraisal.
Characteristics of the GLs and RCs
Table 2 summarizes the information relative to the fifty-
five identified GLs and RCs encompassing iNMDs.
A Amino acid and organic acid metabolism
B Purine, pyrimidine and neurotrasmitter metabolism
C Carbohydrate metabolism
D Lipid metabolism
E Vitamin and non protein cofactor metabolism and transport
F Porphyrin and hem metabolism
G Mineral absorption and transport
H Energy metabolism
I Lysosomal and lysosomal-related organelles
J Peroxisomes
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GLs and RCs were identified for almost all the sub-
types of iNMDs, except for disorders of purine, pyrimi-
dine and other neurotransmitter metabolism (group B),
lipid metabolism (group D) and peroxisomal disorders
(group J). The groups of disorders highly differed in the
number of associated GLs and RCs, since documents
encompassing disorders of vitamin and non protein co-
factor metabolism and transport (group E), porphirin
and hem metabolism (group F) and energy metabolism
(group H) were covered by a small number of GLs and
RCs (n = 2, n = 1, n = 3, respectively). In contrast, the
disorders associated with lysosomal and lysosomal-
related organelles were the most encompassed by GLs
and RCs (n = 27, Fig. 2a). These numbers did not
necessarily correlate with the number of disorders in
each group. For instance, the number of disorders
associated to lysosome and lysosomal-related organ-
elles (group I, n = 115) was lower than the number of
disorders of energy metabolism (group H, n = 155),
even though the number of GLs and RCs was
ninefold higher in the former group (n = 27 and n = 3,
respectively, Fig. 2b).
Six of the identified documents were about groups
of disorders (11 %), while the remaining 49 pubblica-
tions focused on one unique disorder and globally
covered twenty different diseases (Table 2). Moreover,
52 % of the considered pathological conditions were
covered by only one document. In contrast, GLs and
RCs about Gaucher disease, Fabry disease, and muco-
polysaccharidoses (MPSs) were reported in seven
(Gaucher disease) and eight (Fabry disease and MPSs)
different publications (Additional file 1: Table S1 and
Fig. 2c).
Although the number of new documents/year has
been quite stable all over the last first decade, the overall
frequency of GLs and RCs about iNMDs has signifi-
cantly increased over time (Fig. 3a and b).
The analysis of the country of origin of the authors
revealed that 29.1 % of the GLs and RCs were from
Europe, 23.6 % from USA and the remaining 42.3 %
Table 1 AGREE II instrument-domains and items
Domain Item
Number Content
1. Scope and purpose 1 The overall objective(s) of the guideline is (are) specifically described
2 The clinical question(s) covered by the guideline is (are) specifically described
3 The population to whom the guideline is mean to apply is specifically described
2. Stakeholder involvement 4 The guideline development group includes individuals from all relevant professional groups
5 The views and preferences of the target population have been sought
6 The target users of the guideline are clearly defined
3. Rigour of development 7 Systematic methods were used to search for evidence
8 The criteria for selecting the evidence are clearly described
9 The strengths and limitations of the body of evidence are clearly described
10 The methods for formulating the recommendations are clearly described
11 The health benefits, side effects, and risks have been considered in formulating the recommendations
12 There is an explicit link between the recommendations and the supporting evidence
13 The guideline has been externally reviewed by experts prior to its publication
14 A procedure for updating the guideline is provided
4. Clarity of presentation 15 The recommendations are specific and unambiguous
16 The different options for management of the condition or health issue are clearly presented
17 Key recommendations are easily identifiable
5. Applicability 18 The guideline describes facilitators and barriers to its application
19 The guideline provides advice and/or tools on how the recommendations can be put into practice
20 The potential resource implications of applying the recommendations have been considered
21 The guideline presents monitoring and/or auditing criteria
6. Editorial independence 22 The views of the funding body have not influenced the content of the guideline
23 Competing interests of guideline development group members have been recorded and addressed
Overall assessment 1 Overall quality of this guideline
2 Would you recommend this guideline for use?
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Table 2 Characteristics of the guidelines and recommendations
Authors/titles Year Disorder Authors (n) Countries (n) Affiliations (n) Topics
Disorders of amino acid and other organic acid metabolism
Arnold GL [22] 2008 3-methylcrotonyl CoA carboxylase deficiency 15 2 15 Diagnosis, management
Baumgartner MR [37] 2014 Methylmalonic and propionic acidemia 25 12 21 Screening, diagnosis,
management, follow-up
Frazier D [38] 2014 Maple syrup urine disease 9 1 9 Management
Haberle J [19] 2012 Urea cycle disorders 15 4 14 Screening, diagnosis,
management, follow-up
Kölker S [20] 2011 Glutaric aciduria type I 19 8 15 Screening, diagnosis,
management
Kölker S [39] 2007 Glutaric aciduria type I 19 10 15 Screening, diagnosis,
management
NIH CDP [40] 2001 Phenylketonuria 14 1 14 Screening, diagnosis,
management, follow-up
Vockley J [41] 2014 Phenylketonuria 10 1 10 Screening, diagnosis,
management, follow-up
Disorders of carbohydrate metabolism
Barba-Romero MA [42] 2012 Pompe disease 13 1 13 Diagnosis, management,
follow-up
Cochat P [43] 2012 Primary hyperoxaluria Type 1 18 6 16 Screening, diagnosis,
management
Cupler EJ [44] 2012 Pompe disease 7 1 7 Diagnosis, management
Kishnani PS [45] 2014 Glycogen storage disease type I 15 1 8 Diagnosis, management
Kishnani PS [46] 2010 Glycogen Storage Disease Type III 16 1 10 Screening, diagnosis,
management
Kishnani PS [47] 2006 Pompe disease 22 3 15 Screening, diagnosis,
management, follow-up
Rake JP [48] 2002 Glycogen storage disease type I 6 4 4 Diagnosis, management,
follow-up
Visser G [49] 2002 Glycogen Stoage Disease type I 8 5 6 Management
Winchester B [50] 2008 Pompe disease 29 17 25 Diagnosis
Disorders of vitamin and non protein cofactor metabolism and transport
BCMSC [51] 2011 Cobalamin deciciency unclear 1 unclear Diagnosis, management,
follow-up
Devalia V [52] 2014 Cobalamin and folate disorders 3 2 3 Screening, diagnosis,
management
Disorders of porphyrin and haem metabolism
Stein P [53] 2013 Porphyria 5 1 5 Diagnosis, management
Disorders of mineral absorption and transport
Bacon BR [54] 2011 Hemochromatosis 5 2 5 Screening, diagnosis,
management
BCMA [55] 2013 Hemochromatosis Unclear 1 Unclear Screening, diagnosis,
management
EASL [56] 2012 Wilson Disease 8 Unclear Unclear Screening, diagnosis,
management
Qaseem A [57] 2005 Hemochromatosis 6 1 5 Screening
Roberts EA [58] 2003 Wilson Disease 2 2 2 Diagnosis, management
Disorders of energy metabolism
Angelini [23] 2006 Fatty acid mitochondrial disorders 6 4 5 Diagnosis, management
Arnold GL [59] 2009 Very long chain acyl-CoA dehydrogenase
deficiency
14 2 14 Diagnosis, management
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documents were the result of a collaboration among
authors coming from different continents or Ameri-
can countries (miscellanueous origin) (Fig. 3c).
Finally, 87.3 % of the GLs and RCs covered more than
one topic and dealt principally with the diagnosis (80 %)
and management (91 %) of the disease. Screening and
Table 2 Characteristics of the guidelines and recommendations (Continued)
Finsterer J [60] 2009 Mitochondrial disorders 18 12 18 Diagnosis
Disorders of lysosomal and lysosomal-related organelles
Andersson [61] 2005 Gaucher disease 10 1 10 Management, follow-up
Bennett RL [62] 2002 Fabry disease 9 1 8 Diagnosis, management,
follow-up
Biegstraaten M [63] 2015 Fabry disease 34 15 29 Management
Charrow J [64] 2004 Gaucher disease 11 1 10 Diagnosis, management,
follow-up
de Ru MH [65] 2011 Mucopolysaccharidosis type I 16 6 14 Management
Desnick RJ [66] 2003 Fabry disease 9 2 9 Diagnosis, management,
follow-up
Eng CM [67] 2006 Fabry disease 13 4 11 Diagnosis, management,
follow-up
Fahnehjelm KT [68] 2012 Mucopolysaccharidosis 7 5 5 Diagnosis, management
Giugliani R [69] 2007 Mucopolysaccharidosis VI 3 3 3 Diagnosis, management,
follow-up
Grabowski GA [70] 2004 Gaucher disease 11 5 10 Diagnosis, management
Kaplan P [24] 2013 Gaucher disease 11 9 11 Diagnosis, management,
follow-up
Kes VB [71] 2013 Fabry disease 16 1 11 Screening, diagnosis,
management, follow-up
Laney DA [72] 2013 Fabry disease 9 1 9 Screening, diagnosis,
management, follow-up
Langereis EJ [36] 2013 Mucopolysaccharidosis type I 17 8 15 Diagnosis, management,
follow-up
Muenzer J [35] 2012 Mucopolysaccharidosis type II 11 6 11 Management, follow-up
Muenzer J [73] 2009 Mucopolysaccharidosis type I 12 6 Unclear Diagnosis, management,
follow-up
Ortiz A [74] 2008 Fabry disease 6 5 6 Diagnosis, management,
follow-up
Patterson MC [25] 2012 Niemann-Pick disease type C 6 5 6 Diagnosis, management,
follow-up
Peters C [75] 2003 Hematopoietic cell transplantation for IMDs Unclear Unclear 2 Management, follow-up
Scarpa M [34] 2011 Mucopolysaccharidosis type II 26 14 25 Screening, diagnosis,
management
Solanki GA [76] 2012 Mucopolysaccharidosis type VI 13 4 13 Diagnosis, management,
follow-up
Terryn W [77] 2013 Fabry disease 9 5 9 Screening, diagnosis,
management, follow-up
Vellodi A [78] 2001 Gaucher disease 8 6 8 Maganement, follow-up
Vom Dahl S [79] 2006 Gaucher disease 7 4 7 Follow-up
Wang RY [80] 2011 Lysosomal storage diseases 4 1 5 Screening, diagnosis,
management, follow-up
Weinreb NJ [26] 2004 Gaucher disease 25 14 24 Diagnosis, follow-up
Wraith JE [81] 2009 Niemann-Pick disease type C 13 10 13 Screening, diagnosis,
management, follow-up
NIH CDP National institutes of health consensus development panel, BCMSC British Columbia medical services Commission, BCMA British Columbia medical
association, EASL European association for study of liver
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follow-up-related issues were encompassed by 34 % and
55 % of the documents, respectively. No GLs and RCs
have been developed for the follow-up of disorders of
porphirin and hem metabolism (group F), mineral ab-
sorption and transport (group G) and energy metabolism
(group H, Table 2 and Fig. 3d).
The level of recommendation of the GLs and RCs was
determined by the number of items scoring ≥50 %. The
AGREE II analysis revealed that 25 % of the identified
GLs were strongly recommended (SR), 64 % recom-
mended (R), and 11 % not recommended (NR, Fig. 4a).
All the documents had at least one item scoring ≥50 %
(Table 3). We excluded from the subsequent statistical
analysis the unique document relative to disorders of
porphirin and hem metabolism (group F).
Overall quality assessment of GLs and RCs
In this domain, the appraiser is invited to judge the overall
quality of the GL and to indicate whether she/he would
recommend it for use.
The range and mean ± SD of the overall quality assess-
ment (OQA) score for this domain were 25–92 % and
63 % ± 15 % (Table 3 and Fig. 4b). Interestingly, although
we did not find any statistically significant differences
among groups, the OQA of the GLs and RCs about
iNMDs increased over the years (Fig. 4c).
A further 3-point scale (1 = not recommended, NR;
2 = recommended with modifications, R +M, and 3 =
recommended, R) was introduced in the analysis, pro-
viding an additional overall judgment on whether the
GLs or RCs should be recommended for use (Table 3).
For this item, the range and mean ± SD of the overall
score were 1.5–3 % and 2.2 % ± 0.4 %. Almost all the GLs
and RCs were recommended, since they scored ≥2, except
for six documents (11 %) that were not recom-
mended. On the other hand, appraisers considered
that 83 % of the GLs and RCs required modifications.
Of note, two out of three documents recommended
without modifications by both appraisers belonged to
the group of amino acid and organic acid metabolism
(group A).
The quality of a GL is supposed to improve when it
is developed by experienced experts coming from dif-
ferent countries, or distinct professional categories.
For this reason, we next wondered whether the over-
all quality of the GLs and RCs could depend on the
number of authors, countries or affiliations to which
authors belong. Figure 5a-c shows that a direct cor-
relation between the OQA and these parameters could
not be determined, although a non statistically significant
increase in the OQA was observed for higher number of
authors and affiliations.
Fig. 2 Characteristics of the identified GLs and RCs. a Number of the GLs and RCs selected for each group of disorders. b Number of disorders
belonging to each group. c Percentage of disorders for which 1 to 8 different GLs and RCs were identified. A: amino acid and organic acid
metabolism (n = 8); B: Purine, pyrimidine and neurotrasmitter metabolism (n = 0); C: carbohydrate metabolism (n = 9); D: lipid metabolism (n = 0);
E: vitamin and non protein cofactor metabolism and transport (n = 2); F: porphyrin and hem metabolism (n = 1); G: mineral absorption and
transport (n = 5); H: energy metabolism (n = 3); I: lysosomal and lysosomal-related organelles (n = 27); J: peroxisomes (n = 0)
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Domain 1: scope and purpose
This domain considers whether the overall objectives of
the GL, the health questions covered by the GL and the
population whom the GL is directed to are specifically
described. The range and mean ± SD of the overall score
for this domain were 56–100 % and 78 % ± 18 %. Table 3
and Fig. 6a report the score recorded for each GL and
the overall score obtained by the different groups of
disorders. The scores were comparable for all the con-
sidered groups. None of the GLs or RCs scored <50 %.
Domain 2: stakeholder involvement
This domain evaluates whether the GL development
group includes individuals from all relevant professional
groups, the views and preferences of the target popula-
tion have been sought, and the target users of the GL
are clearly defined. The range and mean ± SD of the
overall score for this domain were 8–92 % and 48 % ±
23 % (Table 3 and Fig. 6b). Almost half of the overall
GLs and RCs, as well as all the documents related to dis-
orders of vitamin and non protein cofactor metabolism
and transport (group E) and mineral absorption and
transport (group G), scored < 50 %. In addition, we also
found statistically significant differences in the scores
obtained by the different groups in item 4, which refers
to the composition of the GL development group
(Fig. 7a). For item 5, referring to the involvement of the
target population in the elaboration of the GLs, 75 % of
the documents had a score between 1 and 2, indicating
that most of them did not consider patients or public in
the process (data not shown).
Domain 3: rigour of development
This domain relates to the method used to search and
select the evidence and to formulate the GL. It also
focuses on the health benefits, side effects, and risks that
should be considered when formulating the recommen-
dations. The range and mean ± SD of the overall score
for this domain were 13–95 % and 48 % ± 22 %. (Table 3
and Fig. 6c).
Whereas all the documents for disorders of amino acid
and organic acid metabolism (group A) obtained a mean
score ≥50 %, thirty-one GLs and RCs (56 %) presented
scores < 50 % for this domain.
The statistical analysis of the distinct items revealed
that the seven groups of disorders obtained different
Fig. 3 Publication date, origin and topics of the identified GLs and RCs. a Number of GLs and RCs published between 2000 and 2015. b Correlation
between year of publication from 2000 to 2014 and number of GLs or RCs, linear regression. c Country of origin of the GLs and RCs. For each
document, the countries of origin of all the authors were analyzed and GLs and RCs were classified as: from Europe, from USA or from miscellaneous
origin (different continents or different American countries). Data are expressed as relative percentage referred to total GLs and RCs covering the same
group of disorders. d Topics covered by the identified GLs and RCs. A: amino acid and organic acid metabolism (n = 8); C: carbohydrate metabolism
(n = 9); E: vitamin and non protein cofactor metabolism and transport (n = 2); F: porphyrin and hem metabolism (n = 1); G: mineral absorption and
transport (n = 5); H: energy metabolism (n = 3); I: lysosomal and lysosomal-related organelles (n = 27)
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scores in items 7, 8, 9, 10 and 13 (Fig. 7b-f ). Item 13
considers whether the GL has been externally reviewed
by experts prior to its publication. For this items, only
30 % of the documents obtained a score > 3, indicating
that the majority did not undergo an external revision
prior to submission for publication or did not provide
sufficient information. Item 14 judges if a procedure
for GL updating has been established and 73 % of
the documents provided scarce information (score ≤3,
data not shown).
Domain 4: clarity of presentation
This domain examines whether the RCs are specific
and unambiguous, the different options for manage-
ment are clearly presented and key RCs are easily
identifiable. The range and mean ± SD of the overall
score for this domain were 31–100 % and 74 % ±
20 %. Table 3 and Fig. 6d show that all the groups of
disorders presented a comparable score for this
domain and no statistically significant difference was
observed. Only two documents (3.6 %), belonging to
the disorders of energy metabolism (group H) and
lysosomal and lysosomal-related organelles (group I),
presented scores < 50 %.
Domain 5: applicability
This domain examines whether the GL describes facilita-
tors and barriers to its application, explains how the RCs
could be put into practice and considers the potential re-
source implications of applying the RCs. The range and
mean ± SD of the overall score for this domain were
8–73 % and 39 % ± 16 % (Table 3 and Fig. 6e). Collectively,
76 % of all the identified documents had a score < 50 %
and all the GLs and RCs about mineral absorption and
transport (group G) and energy metabolism (group H)
obtained scores < 50 %. Analyzing the distinct items, we
observed that 38, 58, 80 and 24 % of the documents
achieved scores ≤3 for item 18, 19, 20, and 21, re-
spectively. In particular, for item 20 (potential cost
impact of the GL) the majority of the identified GLs
did not sufficiently consider the cost effectiveness or
implications for budget of applying the recommenda-
tions (data not shown).
Domain 6: editorial independence
This domain assesses whether the views of the funding
body have not influenced the content of the GL and
whether the competing interests of GL development
group members have been recorded and addressed. The
range and mean ± SD of the overall score for this
Fig. 4 Overall quality of the identified GLs and RCs. a Overall recommendation: percentage of strongly recommended (SR), recommended (R)
and not recommended (NR) GLs and RCs. Data are expressed as relative percentage referred to total GLs and RCs covering the same group of
diseases. b Overall quality assessment (OQA) of GLs and RCs. Data are presented as mean ± SD. c Correlation between OQA and year of publication,
linear regression. d Grade of recommendation (GR) of GLs and RCs (scores from 1 = not recommended to 3 = recommended without modifications).
Data are presented as mean ± SD. A: amino acid and organic acid metabolism (n = 8); C: carbohydrate metabolism (n = 9); D: lipid metabolism;
E: vitamin and non protein cofactor metabolism and transport; G: mineral absorption and transport (n = 5); H: energy metabolism (n = 3); I: lysosomal
and lysosomal-related organelles (n = 27)
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Table 3 Results of AGREE II appraisal for all the identified guidelines and recommendations
Authors OR D1 D2 D3 D4 D5 D6 OQA GR
Disorders of amino acid and other organic acid metabolism
Arnold GL R 67 44 52 61 29 0 50 2
Baumgartner MR SR 94 86 95 94 46 50 92 3
Frazier D SR 78 92 83 97 65 58 92 2.5
Haberle J SR 83 89 90 89 58 96 92 3
Kölker S-2011 SR 56 58 83 92 63 100 75 2.5
Kölker S-2007 R 67 36 91 89 29 100 75 2.5
NIH CDP SR 89 86 86 81 73 4 58 2.5
Vockley J R 89 31 60 78 48 54 75 2
Disorders of carbohydrate metabolism
Barba-Romero MA R 80 61 53 83 31 50 75 2
Cochat P R 72 28 27 92 31 33 58 2.5
Cupler EJ R 64 64 46 67 41 63 75 2
Kishnani PS-2014 SR 86 61 47 100 58 63 75 2.5
Kishnani PS-2010 R 89 61 50 83 48 33 67 2
Kishnani PS-2006 SR 83 56 44 56 50 75 67 2
Rake JP R 94 17 27 92 25 0 58 2
Visser G R 83 19 23 83 23 0 50 2
Winchester B NR 72 36 14 53 25 67 42 1.5
Disorders of vitamin and non protein cofactor metabolism and transport
BCMSC R 94 31 51 61 27 0 67 2.5
Devalia V R 83 33 71 94 67 83 83 2
Disorders of porphyrin and hem metabolism
Stein P SR 89 81 56 89 56 50 75 2.5
Disorders of mineral absorption and transport
Bacon BR R 56 44 75 83 46 17 67 2
BCMA R 94 8 13 81 27 0 58 2
EASL R 67 28 49 86 35 38 67 2
Qaseem A NR 100 36 27 50 23 42 33 1.5
Roberts EA R 67 17 32 78 33 0 58 2
Disorders of energy metabolism
Angelini NR 64 8 36 31 8 21 33 1.5
Arnold GL R 86 67 61 72 38 0 67 2
Finsterer J R 75 53 48 72 19 0 58 2.5
Disorders of lysosomal and lysosomal-related organelles
Andersson R 83 33 29 67 25 0 58 2.5
Bennett RL SR 92 86 69 78 52 46 83 3
Biegstraaten M SR 64 81 65 64 42 71 67 2
Charrow J R 81 56 43 69 33 13 58 2
de Ru MH SR 89 50 63 89 54 58 75 2.5
Desnick RJ NR 64 22 40 53 48 46 42 2
Eng CM R 92 42 45 89 46 0 67 2.5
Fahnehjelm KT R 75 58 32 81 38 50 75 2.5
Giugliani R R 75 56 56 67 29 38 58 2
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Table 3 Results of AGREE II appraisal for all the identified guidelines and recommendations (Continued)
Grabowski GA R 72 33 27 56 33 0 50 2
Kaplan P R 78 39 29 78 38 100 83 2
Kes VB R 61 33 29 56 21 0 50 2
Laney DA R 94 92 46 78 46 83 67 2.5
Langereis EJ R 86 72 58 53 23 46 58 2
Muenzer J-2012 R 92 53 33 69 40 92 50 2.5
Muenzer J-2009 R 69 36 28 69 42 50 58 2
Ortiz A R 58 31 40 61 23 92 50 2.5
Patterson MC R 78 28 38 78 42 4 67 2
Peters C NR 64 39 25 33 13 0 25 1.5
Scarpa M SR 61 75 61 89 42 58 75 2.5
Solanki GA R 72 39 24 61 54 100 50 1.5
Terryn W SR 81 44 67 78 58 54 67 2.5
Vellodi A NR 83 61 30 72 17 0 42 1.5
Vom Dahl S R 89 36 54 56 31 83 50 2
Wang RY SR 92 64 53 92 67 92 83 2.5
Weinreb NJ R 67 39 30 67 17 4 50 2
Wraith JE R 83 28 46 83 42 0 83 3
OR Overall recommendation, D Domain, OQA Overall quality assessment, GR Grade of recommendation, NIH CDP National institutes of health consensus development
panel, BCMSC British Columbia medical services commission, BCMA British Columbia medical association, EASL European association for study of liver, SR Strongly
recommended, R Recommended, NR Not recommended domain scores were calculated as described in Methods
Fig. 5 Correlation between quality of the GLs/RCs and number of authors, countries or affiliations. Linear regression analysis was used to determine
whether the overall quality assessment (OQA) of a GL could depend on the number of authors (a), countries (b) or affiliations (c) involved in its elaboration
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domain were 0–100 % and 41 % ± 35 %. (Table 3 and
Fig. 6f ). No statistically significant difference was ob-
served among groups. Only 47 % of total GLs and RCs
had a score ≥50 % and none of the documents related to
disorders of energy metabolism (group H) and mineral
absorption and transport (group G) reached this score
for this domain.
Gaucher disease and Fabry disease were the most studied
diseases
We next focused on two lysosomal storage disorders,
Gaucher disease and Fabry disease, encompassed by
seven and eight different GLs and RCs, respectively.
Gaucher disease is an inherited disorder with an esti-
mated birth prevalence of 1:40,000 to 1:60,000, caused
by deficient activity of the lysosomal enzyme gluco-
cerebrosidase [11, 12]. Fabry disease affects approxi-
mately 1:40,000-170,000 individuals and it is caused
by a deficiency of the lysosomal hydrolase α- galacto-
sidase A [13].
The aim was to determine whether the quality and
rigour of the GLs and RCs improved over time. For this
purpose, the scores referring to domains 1–6 and to the
OQA domain were analyzed. For Gaucher disease, we
did not find an increase in the scores referring to
domains 1–6. However, a statistically significant increase
in the OQA was observed (Additional file 1: Table S1
and Fig. 8a and b).
By contrast, for Fabry disease no improvement was
observed in none of the appraised domains (Fig. 8c and d).
Discussion
This is the first systematic estimation of the number and
methodological quality of all existing GLs and RCs about
iNMDs, which have been reclassified inside the activities
of the EU funded project InNerMeD-I- Network. The
project InNerMeD-I-Network is aimed to group the
most vast multidisciplinary network in order to collect,
exchange and share validated information among scien-
tific communities, health professionals, patients, patient
associations, public health authorities, pharmaceutical
companies and other interested parties. One of the focus
of this project is the analysis of existing and the elabor-
ation of new GLs and RCs that will provide practical
support for the diagnosis and treatment of iNMDs.
To this aim, for the analysis of existing GLs and RCs
for iNMDs, we have selected the AGREE II instrument,
considered one of the best choice to conduct a compre-
hensive GL appraisal [7, 14]. Importantly, AGREE II tool
does not evaluate the medical/scientific content validity
or the evidence base underlying a RC, but the rigour
Fig. 6 Results of AGREE II appraisal for domains 1–6. The identified GLs and RCs were scored on a 7-point scale for the 23 items belonging to domain
1 (a), domain 2 (b), domain 3 (c), domain 4 (d), domain 5 (e) and domain 6 (f). Data are presented as mean ± SD of values obtained by each group of
disorders in each domain. A: amino acid and organic acid metabolism (n = 8); C: carbohydrate metabolism (n = 9); E: vitamin and non protein cofactor
metabolism and transport (n = 2); G: mineral absorption and transport (n = 5); H: energy metabolism (n = 3); I: lysosomal and lysosomal-related
organelles (n = 27)
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and transparency applied during GL development [15].
Thus, the performed analysis can be considered as a
valuable tool for the elaboration of new GLs and RCs for
iNMDs, since it provides methodological models for GL
developers. On the other hand, it also offers a precise
and updated picture about the existing GLs for iNMDs.
This review could be useful for practical clinical pur-
poses but also as an overview to detect what disorders
do not currently have any official guide.
AGREE II scores indicate that the overall methodo-
logical quality of the GLs and RCs for selected
iNMDs is acceptable (although very few of them ob-
tained a score ≥50 % in at least five items), and in-
creasing over time. In addition, in all the appraised
GLs and RCs the authors sufficiently describe the
overall objectives, the covered health questions and
the population whom they are directed.
Similarly, the appraisers judged that for most of the
documents, the RCs were sufficiently specific, unam-
biguous, and easily identified, and that the different
options for diagnosis or management were clearly pre-
sented. The availability of identifiable information facili-
tates the task of the health professionals when choosing
the proper guidance.
We choose the year 2000 as lower limit for GL and
RC search because we consider that from this year
onwards experts in iNMDs have acquired more aware-
ness about the necessity to provide guidance, as well as
to collaborate and create networks. This may be due to
the fact that in the last 15 years the number of patients
who have been successfully diagnosed for iNMDs in-
creased, also thanks to the availability of more precise
and reliable diagnostic techniques. In this regard, we ob-
served a substantial increase in the number of GLs and
RCs for iNMDs, especially in the last few years.
Interestingly, only 23 % of the 251 documents identified
in the first search met the inclusion criteria and we often
observed a widespread misuse of the term "guideline" that
was utilized for systematic reviews, algorithms or letters.
Indeed, until now the most common way of providing an
overview or global knowledge about a particular disease
or group of disorders in the field of iNMDs was by elabor-
ating extensive systematic reviews of the published litera-
ture. The resultant documents were often used by health
professionals as GLs or RCs. In the last years, the
tendency changed and groups of experts meet with the
exclusive purpose of writing well-structured evidence-
based GLs [16, 17].
However, we could not find GLs and RCs for most of
iNMDs, although disorders including Pompe disease,
Gaucher disease, Fabry disease and MPSs were covered
by at least three GLs or RCs. This disproportionate
Fig. 7 Results of AGREE II appraisal for individual items. Scores obtained by the identified GLs and RCs on a 7-point scale for item 4 (a), item 7
(b), item 8 (c), item 9 (d), item 10 (e) and item 13 (f). Data are presented as mean ± SD of values obtained by each group of disorders in each
item. A: amino acid and organic acid metabolism (n = 8); C: carbohydrate metabolism (n = 9); E: vitamin and non protein cofactor metabolism and
transport (n = 2); G: mineral absorption and transport (n = 5); H: energy metabolism (n = 3); I: lysosomal and lysosomal-related organelles (n = 27)
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distribution of GLs and RCs could imply that guidance
is prevalently provided for potentially treatable disorders,
for which fully tested or still experimental therapies
already exist. In this respect, we also observed that
50-100 % of the GLs and RCs for Pompe disease, Gaucher
disease, Fabry disease and MPSs were partially or totally
funded by pharmaceutical companies, which may be par-
ticularly interested in the dissemination of RCs that pro-
mote the use of their own treatments. This observation
may also entails that GL development is a costly process
that may require external funding to be realized and may
explain why most of the iNMDs still do not have guidance
for their diagnosis or treatment.
On the other hand, it has to point out that often
GLs and RCs not even exist for several treatable
disorders, including different vitamin (thiamine, ribo-
flavine, biotine, vitamin E)-responsive diseases, the
glucose transporter type 1 (Glut1) deficiency, or the
cerebrotendinous xanthomatosis (CXT), among others.
In this case, lack of GLs could be ascribed to a still
insufficient information about the phenotype and the
progression of the disorder, or the correct treatment
requirement.
However, two different European networks are cur-
rently working on the elaboration of GLs and RCs for
treatable homocystinurias and neurotrasmitter defects
(unpublished data).
The rarity of iNMDs may also explain the lack of avail-
able GLs for their screening, diagnosis, management or
follow-up. In fact, few clinical trials exist and the
Fig. 8 Results of AGREE II appraisal for Gaucher disease and Fabry disease. GLs and RCs for Gaucher disease (a) and Fabry disease (c) were scored
on a 7-point scale for the 23 items belonging to domain 1–6. Numbers indicate the scores obtained in each domain by GLs and RCs grouped by
year of publication. Correlation between overall quality assessment (OQA) and year of publication was determined for all existing GLs and RCs for
Gaucher disease (b) and Fabry disease (d), linear regression
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published evidence often consists of isolated case reports
and is not sufficient to elaborate a GL. Similarly, expert
opinion is often inadequate in the case of ultra-rare disor-
ders, because clinicians can see an individual condition
only rarely in a career [18]. Nevertheless, the knowledge
in the field of iNMDs has enormously increased in the last
decades. Thus, the establishment of international net-
works composed by experts encompassing all the health
specialties related to iNMD disorders could dramatically
enhance the number of GLs for practice. In particular,
more attention should be paid to disorders for which
therapeutic possibilities already exist, in order to es-
tablish the bases for a proper treatment or follow-up
of the patients.
Some recent GLs, such as those about urea cycle
disorders (UCDs) or organic acidurias (OA) among
others, have been created in the context of European-
International projects funded by the European Com-
mission, where consortiums composed by many coun-
tries and expert centers were formed in order to
elaborate specific plans for GL development [19, 20].
This strategy could explain why GLs and RCs cover-
ing disorders of amino acid and organic acid metabol-
ism obtained the highest scores in almost all the
domains. Indeed, our results show that although the
correlation was not statistically significant, the overall
quality of the GLs and RCs was higher when the
number of authors or affiliations involved in its devel-
opment increased.
The AGREE II analysis revealed that the elaboration of
most of the selected GLs did not involve the target
population (patients or public). This could be due to
different factors, such as the difficulty to identify and
recruit patients or representatives of the public or the
discrepancy between the perspectives of expert and non-
expert members. In addition, the target population often
does not have familiarity with the scientific and medical
terminology [21]. Nonetheless, an effort should be done
to increase the collaboration between experts and
patients or public, by providing them with scientific
support, training and mentoring. This could lead to
more relevant and understandable GLs or to the produc-
tion of additional material, such as quick reference
guides or leaflets that could assist patients and families
along the course of the disease.
Our data also showed that the majority of the GLs
and RCs were published without an external review
prior to submission for publication. The GL revision
by one or more external experts working in the same
subject area would likely improve the methodological
quality of the recommendations. In fact, external re-
viewers coming from different countries or medical
fields could provide a more comprehensive view
about diagnosis or management options for iNMDs.
On the other hand, an expert external advice prior to
the elaboration of the guidance would be certainly valu-
able, in order to ensure the adoption of the most rigorous
and structured possible methodology.
We observed that 73 % of the GLs and RCs did not pro-
vide a procedure for their updating, and some disorders
were covered by only one document published several
years ago [22, 23]. On the other hand, four of the docu-
ments are revised version of previously published GLs and
RCs [20, 24–26]. The updated version of previous GLs
and RCs may present an improve in the OQA [24], or in
the overall recommendation grade [20]. However, the
small number of updated documents we identified with
our search is not sufficient to determine whether the
methodological quality of a guidance increases in its later
versions. The updating of a GL should collect all the new
evidence reported as well as information about the devel-
opment of new technologies in diagnosis and treatment,
thus reducing the variability among the documents pub-
lished about the same disorders. However, very little infor-
mation is available so far to indicate when a GL should be
updated [27–29]. In this respect, we observed that the
time between the first and the updated versions of the
same GLs and RCs for iNMDs ranged between 3 and
9 years.
The frequency of iNMDs varies among different popu-
lations, and higher rate of consanguinity normally results
in a significantly higher incidence of the disease. For ex-
ample, the frequency of methilmalonic acidemia (MMA)
is higher in Saudi Arabia, whereas glutaric aciduria type
1 (GA1) is more recurrent in the Old Order Amish in
United States. This heterogeneous distribution of iNMD
might imply that different strategies should be adopted
by each country according to its possibilities. Indeed,
because of the local economic conditions, some treat-
ments, medical instruments or support infrastructure
may be available in one country, but eventually not in
another one [30, 31]. In this regard, none of the
appraised documents referred to suitable alternatives for
more vulnerable regions or countries, although an as-
sessment of the implementation and adaptation of GLs
for UCDs has been recently reported [31].
In addition, most of the analyzed documents did not
consider neither the economical impact of applying the
GL, probably because it may be difficult to predict costs
and benefits, especially for long-term treatments [16].
Finally, none of the appraised GLs and RCs evaluated
the risks versus benefits related to different social, eco-
nomic or geographic realities.
This systematic search may present some limitations.
First, we cannot exclude that we may have overlooked
important GLs and RCs. Moreover, we only included
documents in English, so GLs and RCs in other lan-
guages were not considered. Second, GLs were reviewed
Cassis et al. Orphanet Journal of Rare Diseases  (2015) 10:164 Page 16 of 19
by two different appraisers and although a consensus
was reached in case of discrepancy, they might have
different level of understanding of the AGREE II instru-
ment. In addition, since a reference cannot be provided
by the AGREE II instrument, the perception that the
appraiser had of the quality of a GL may have varied for
each document and could be influenced by the compari-
son with the previous one.
Conclusions
Our analysis indicates that more documents are needed to
encompass all the iNMDs that still lack guidance for their
screening, diagnosis, treatment or follow-up. Considering
AGREE II as a valuable tool for GL development, we
observed that many of the existing GLs and RCs do not
respond to the proposed criteria. In particular, new GL
developers should take greater account of aspects that are
still too overlooked. First of all, a GL should contain ac-
curate information about how the evidence is searched,
selected, validated and supporting the RC. Moreover, GL
developers should consider the associated health benefits,
side effects, and risks. In this regard, we also emphasize
the necessity to externally review and update the GLs and
to adapt them to the different social, economic and
cultural realities. Finally, patients and society should be
called to participate in the development of new RCs.
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